Pharmaceutical Products Companies By One Year Return

One Year Return
One Year ReturnEfficiencyMarket RiskExp Return
1DRUG Bright Minds Biosciences
2.58 K
 0.14 
 125.77 
 18.10 
2ELDN Eledon Pharmaceuticals
194.59
 0.19 
 5.07 
 0.95 
3VERA Vera Therapeutics
179.34
 0.00 
 3.60 
(0.01)
4DNTH Dianthus Therapeutics
172.0
(0.02)
 3.64 
(0.08)
5VRNA Verona Pharma PLC
156.69
 0.20 
 2.85 
 0.58 
6DSGN Design Therapeutics
146.06
 0.07 
 5.51 
 0.39 
7ELUT Elutia Inc
137.25
 0.08 
 6.61 
 0.54 
8VKTX Viking Therapeutics
134.59
(0.10)
 5.10 
(0.53)
9DMAC DiaMedica Therapeutics
127.3
 0.16 
 5.24 
 0.85 
10IZTC Invizyne Technologies Common
114.68
 0.39 
 7.75 
 3.05 
11JUNS Jupiter Neurosciences, Common
77.23
 0.32 
 15.80 
 4.99 
12VTVT vTv Therapeutics
66.41
 0.05 
 4.36 
 0.20 
13VCEL Vericel Corp Ord
59.15
 0.13 
 2.68 
 0.34 
14ELVN Enliven Therapeutics
51.31
(0.01)
 3.03 
(0.03)
15GRCE Grace Therapeutics,
26.91
 0.14 
 5.17 
 0.72 
16VNDA Vanda Pharmaceuticals
24.16
 0.02 
 2.61 
 0.04 
17VTRS Viatris
17.56
 0.08 
 2.20 
 0.17 
18SEPN Septerna, Common Stock
13.46
 0.15 
 5.64 
 0.87 
19TLX Telix Pharmaceuticals Limited
4.42
 0.08 
 2.30 
 0.19 
20ENGN enGene Holdings Common
4.07
 0.06 
 8.49 
 0.47 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading. Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.